



Obesity Is a Risk Factor for Greater COVID-19 Severity

Diabetes Care 2020;43:e72–e74 | <https://doi.org/10.2337/dc20-0682>

Feng Gao,¹ Kenneth I. Zheng,²
Xiao-Bo Wang,³ Qing-Feng Sun,⁴
Ke-Hua Pan,⁵ Ting-Yao Wang,⁶
Yong-Ping Chen,² Giovanni Targher,⁷
Christopher D. Byrne,⁸ Jacob George,⁹
and Ming-Hua Zheng^{2,10,11}

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention (1). Obesity commonly aggravates the severity of respiratory diseases, but it is currently not known whether obese patients are also more likely to have greater COVID-19 severity of illness. We investigated the association between obesity and COVID-19 severity of illness among patients with laboratory-confirmed SARS-CoV-2 infection.

We enrolled adult patients with COVID-19 from three hospitals in China between 17 January 2020 and 11 February 2020. Seventy-five patients were diagnosed as obese (i.e., case subjects). We randomly matched each case subject with one control subject (nonobese) by sex (1:1) and age (± 5 years). The cohort thus comprised 150 patients with COVID-19. The study protocol was approved by local ethics committees of the three hospitals.

The requirement for written informed consent was waived due to the retrospective and anonymous nature of the study.

COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase PCR assay of oropharyngeal swab specimens. COVID-19 severity of illness was assessed during hospitalization and classified into four clinical subtypes (i.e., mild, moderate, severe, or critically ill) based on management guidelines (2). Obesity was defined as BMI ≥ 25 kg/m² in this Asian population. Diabetes was determined as either history of diagnosed diabetes, use of antidiabetic drugs, or, in few cases, newly diagnosed diabetes after recovery from acute SARS-CoV-2 infection. Diagnosis of diabetes was made using standard procedures at the three hospitals, based on guidelines of the China Diabetes Society (3). Hypertension and dyslipidemia were diagnosed based on established criteria. All patients denied a history of active

cancer, chronic obstructive or restrictive pulmonary diseases, or other end-stage diseases. Patients received standard treatments according to the Chinese COVID-19 management guidance (7th edition) (2) and were all discharged alive from the hospital.

For statistical purposes, COVID-19 patients were categorized into two groups according to their disease severity as non-severe (i.e., mild and moderate disease, combined) and severe (severe and critical, combined) (2). The association between presence of obesity or increasing BMI values (as exposure measures) and COVID-19 severity (as the outcome measure) was assessed by binary logistic regression analysis. Statistical analyses were two-sided, and significance was set at $P < 0.05$.

The mean age of patients was 48 years, and 62.7% were male. Twenty-nine patients (19.3%) had diabetes; obese patients were more likely to have diabetes than those without obesity

¹Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

²NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

³Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China

⁴Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China

⁵Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

⁶Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

⁷Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

⁸Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, U.K.

⁹Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia

¹⁰Institute of Hepatology, Wenzhou Medical University, Wenzhou, China

¹¹Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China

Corresponding author: Ming-Hua Zheng, zhengmh@wmu.edu.cn

Received 31 March 2020 and accepted 8 April 2020

F.G. and K.I.Z. are co-first authors.

This article is part of a special article collection available at <https://care.diabetesjournals.org/collection/diabetes-and-COVID19>.

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.




Figure 1—A: Prevalence of clinical subtypes of COVID-19 severity among infected patients with and without obesity. B: Association between increasing BMI values and COVID-19 severity.

(24.0% vs. 14.7%). Mean BMI for non-obese and obese patients was 21.8 ± 2.3 and 27.7 ± 2.7 kg/m², respectively. At their hospital admission, obese patients had higher levels of plasma C-reactive protein and lower lymphocyte counts, which are considered two early indicators of severe COVID-19 (2). Notably, obese patients also had a longer hospital stay (median 23 [interquartile range 17–30] vs. 18 [13–24] days; *P* = 0.037) and a greater proportion had severe COVID-19 (33.3% vs. 14.7%, *P* = 0.007 by χ^2 test) (Fig. 1A) compared with non-obese patients. As shown in Fig. 1B, there was a clear dose-effect relationship between increasing values of BMI and the proportion of patients with severe COVID-19.

In the logistic regression analyses, the presence of obesity was associated with an approximately threefold increased risk of having severe COVID-19 (unadjusted odds ratio [OR] 2.91, 95% CI 1.31–6.47). Each 1-unit increase in BMI was also associated with a 12% increase in the risk of severe COVID-19 (unadjusted OR 1.12, 95% CI 1.01–1.23). Notably, the association between obesity (or increasing BMI values) and greater COVID-19 severity remained significant even after adjusting for age, sex, smoking status, hypertension, diabetes, and dyslipidemia (adjusted OR 3.00, 95% CI 1.22–7.38

for obesity, and adjusted OR 1.13, 95% CI 1.01–1.28 for BMI).

To date, the virologic and physiological mechanisms underlying the strong relationship we observed between obesity and COVID-19 severity are poorly understood. It is plausible to hypothesize that more severe COVID-19 in patients with obesity may be the consequence of underlying low-grade chronic inflammation and suppression of innate and adaptive immune responses (4). In addition, the altered microenvironment associated with obesity may support a more diverse viral quasispecies and afford the emergence of potentially pathogenic variants capable of inducing greater disease severity (5). Finally, mechanical dysfunction due to severe obesity may increase the severity of lower respiratory tract infection and contribute to secondary infection (6).

Health care professionals caring for COVID-19 patients should be cognizant of the increased likelihood of severe COVID-19 in obese patients. In particular, the presence of obesity increases the risk of severe illness approximately threefold with a consequent longer hospital stay.

Acknowledgments. The authors thank Hong-Lei Ma (NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University) and Wen-Yue Liu (Department of Endocrinology, the First Affiliated

Hospital of Wenzhou Medical University) for data collection assistance. This work is a part of the PERSONS study.

Funding. This work was supported by a grant from the National Natural Science Foundation of China (81500665) as well as funding from the Ruian Science and Technology Bureau (2020023), High Level Creative Talents from Department of Public Health in Zhejiang Province, and Project of New Century 551 Talent Nurturing in Wenzhou. G.T. is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. C.D.B. is supported in part by the Southampton National Institute for Health Research Biomedical Research Centre (IS-BRC-20004), U.K.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. F.G., K.I.Z., and M.-H.Z. contributed to study concept and design. X.-B.W., Q.-F.S., K.-H.P., T.-Y.W., and Y.-P.C. contributed to acquisition of data. F.G. and K.I.Z. contributed to analysis and interpretation of data. F.G. and K.I.Z. drafted the manuscript. G.T., C.D.B., and J.G. critically revised the manuscript for important intellectual content. M.-H.Z. supervised the study. All authors contributed to the manuscript for important intellectual content and approved the submission. M.-H.Z. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. World Health Organization. Rolling update on coronavirus disease (COVID-19): WHO characterizes COVID-19 as a pandemic. Published 11 March 2020. Accessed 18 March 2020. Available from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>

2. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). 3 March 2020. Accessed 31 March 2020. Available from <https://www.chinadaily.com.cn/pdf/2020/1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7.pdf>
3. Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition). *Chinese Journal of Diabetes Mellitus* 2018;10:4–67
4. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. *J Clin Invest* 2017;127:1–4
5. Honce R, Karlsson EA, Wohlgemuth N, et al. Obesity-related microenvironment promotes emergence of virulent influenza virus strains. *mBio* 2020;11:e03341-19
6. Dixon AE, Peters U. The effect of obesity on lung function. *Expert Rev Respir Med* 2018;12:755–767